chr17-31169895-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001042492.3(NF1):c.484C>T(p.Gln162*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q162Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001042492.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- neurofibromatosis type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
- Moyamoya diseaseInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.484C>T | p.Gln162* | stop_gained | Exon 5 of 58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.4 | c.484C>T | p.Gln162* | stop_gained | Exon 5 of 57 | NP_000258.1 | ||
NF1 | NM_001128147.3 | c.484C>T | p.Gln162* | stop_gained | Exon 5 of 15 | NP_001121619.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:4
- -
This sequence change creates a premature translational stop signal (p.Gln162*) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with neurofibromatosis type 1 (PMID: 17514731). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 481882). For these reasons, this variant has been classified as Pathogenic. -
- -
- -
not provided Pathogenic:2
The NF1 c.484C>T (p.Gln162*) variant causes the premature termination of NF1 protein synthesis. This variant has been reported in the published literature in individuals with neurofibromatosis 1 (NF1) (PMID: 17514731 (2008), Melloni et al (Cancers. 2019; 11(12):1838)), optic pathway glioma (OPG) (PMID: 17514731 (2008)) and malignant peripheral nerve sheath tumor (PMID: 34308366 (2021)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. -
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34308366, 25525159, 31766501, 21278392, 17514731, 28873162, Kiraz_2023, 10712197, 23913538, 35024939) -
Neurofibromatosis, type 1;C0349639:Juvenile myelomonocytic leukemia;C0553586:Café-au-lait macules with pulmonary stenosis;C1834235:Neurofibromatosis, familial spinal;C2931482:Neurofibromatosis-Noonan syndrome Pathogenic:1
- -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
The p.Q162* pathogenic mutation (also known as c.484C>T), located in coding exon 5 of the NF1 gene, results from a C to T substitution at nucleotide position 484. This changes the amino acid from a glutamine to a stop codon within coding exon 5. This alteration has been reported in two siblings with neurofibromatosis type 1 (NF1) and bilateral optic pathway glioma (Kebudi R et al. Pediatr Blood Cancer, 2008 Mar;50:713-5), and has been detected in additional individuals from NF1 cohorts (Melloni G et al. Cancers (Basel). 2019 11;11(12). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at